国际医学(000516) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥1,172,923,244.52, representing a 10.75% increase compared to ¥1,059,092,457.42 in the same period last year[8] - The net profit attributable to shareholders was -¥104,912,277.28, a decrease of 40.37% from -¥74,740,547.17 year-on-year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥89,849,571.13, showing an improvement of 13.05% compared to -¥103,333,541.03 in the previous year[8] - The company reported a basic earnings per share of -¥0.0464, a decline of 41.46% from -¥0.0328 in the same period last year[8] - The total operating profit (loss) was -128,444,926.09, worsening from -95,210,022.42 in the previous period, indicating ongoing operational difficulties[30] - The net profit for the current period was a loss of ¥131,877,100.92, compared to a loss of ¥95,739,550.26 in the previous period, indicating a deterioration in profitability[30] - The total comprehensive loss for the current period was ¥131,877,100.92, compared to a loss of ¥95,739,550.26 in the previous period, reflecting increased financial challenges[30] Cash Flow - The net cash flow from operating activities was ¥219,246,919.94, a slight decrease of 1.65% from ¥222,931,373.21 in the same period last year[8] - The net cash flow from investment activities increased by 61.30% year-on-year, primarily due to reduced cash payments for fixed assets and other long-term assets[12] - The net cash flow from financing activities decreased by 318.11%, mainly due to increased cash payments for debt repayment during the reporting period[12] - Cash inflow from financing activities totaled $199.4 million, down from $350 million[38] - Cash outflow from financing activities amounted to $483 million, compared to $220 million in the previous period[38] - Net cash flow from financing activities was negative at -$283.6 million, contrasting with a positive $130 million last year[38] - The net increase in cash and cash equivalents was -$201.8 million, compared to a decrease of -$2.2 million previously[38] - The ending balance of cash and cash equivalents stood at $742.2 million, down from $1.18 billion at the end of the previous period[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,912,082,200.88, down 3.61% from ¥11,321,135,811.77 at the end of the previous year[8] - The equity attributable to shareholders was ¥3,811,548,583.50, a decrease of 2.47% from ¥3,908,017,195.19 at the end of the previous year[8] - Total current assets decreased from RMB 1,912,895,613.76 to RMB 1,636,434,285.69, a decline of approximately 14.4%[21] - Cash and cash equivalents decreased from RMB 943,962,638.82 to RMB 742,163,400.11, a reduction of about 21.4%[21] - Accounts receivable decreased from RMB 661,684,668.02 to RMB 647,218,042.92, a decrease of approximately 2.2%[21] - Total liabilities decreased from RMB 7,505,045,119.83 to RMB 7,219,424,944.27, a reduction of approximately 3.8%[24] - The equity attributable to the owners of the parent company decreased from RMB 3,908,017,195.19 to RMB 3,811,548,583.50, a decline of about 2.5%[27] - The company reported a decrease in inventory from RMB 78,336,971.70 to RMB 75,929,958.16, a reduction of approximately 3.1%[21] - The long-term equity investments decreased from RMB 1,993,641.32 to RMB 1,666,588.47, a decline of about 16.4%[21] - The company’s short-term borrowings decreased from RMB 604,542,709.10 to RMB 468,123,483.33, a reduction of approximately 22.6%[24] - The total non-current assets decreased from RMB 9,408,240,198.01 to RMB 9,275,647,915.19, a decline of about 1.4%[24] Operating Costs and Expenses - Total operating costs amounted to ¥1,286,778,395.15, up from ¥1,182,081,758.95, reflecting a year-over-year increase of 8.8%[28] - Research and development expenses decreased to ¥1,944,059.66 from ¥3,325,497.80, a reduction of 41.5%[28]